Related Experiment Video
Updated: May 2, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[Atypical contrast enhancement in mucinous prostate cancer : Limitations of the PI-RADS (Prostate Imaging Reporting
Julio Ruben Rodas Garzaro1, Anton Kravchuk1, Johannes Moersler2
1Klinik für Urologie, St. Elisabeth Klinikum Straubing, St.-Elisabeth-Str. 23, Straubing, Deutschland.
Abstract:
Mucinous prostate carcinoma (mucPCa) often evades detection by prostate-imaging reporting and data system (PI-RADS)-based multiparametric magnetic resonance imaging (MRI). We report a case in which atypical dynamic contrast kinetics served as the sole imaging clue leading to the diagnosis of aggressive mucPCa. Neither T2-weighted nor diffusion-weighted sequences suggested malignancy. Only a targeted MRI/ultrasonography (US) fusion biopsy confirmed an International Society of Urological Pathology (ISUP) grade 4 mucPCa. This case underscores the diagnostic limitations of standardized imaging protocols and highlights the critical importance of contrast enhancement in rare histological subtypes.
Related Concept Videos
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies V: Intravenous Urography and Retrograde Pyelography

